Biologics

BIO International 2026 - Mabion Biologics Team

Mabion Biologics at BIO International Convention 2026

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

NMPA approves first bispecific antibody-drug conjugate: a new treatment for nasopharyngeal carcinoma

Co-development in Biopharma Industry

2026: The Era of Co-development in Biopharma Industry

Anna Czubatka-Bieńkowska and Judyta Suskiewicz strengthen strategic biopharma partnerships in Brazil

Strengthening Strategic Biopharma Partnerships in Brazil: Mabion Visits Bio-Manguinhos and IBMP

Official announcement by the Ministry of Health regarding the ruling on the contract for COVID-19 vaccines produced by Pfizer.

The PLN 5.6 Billion Bill for COVID-19 Vaccines

Inside Mabion’s Transformation Gregor Kawaletz on Scaling, Strategy & Biologic CDMO Ambitions

Executing Mabion’s CDMO Vision: Insights from CEO Gregor Kawaletz

Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

Gregor Kawaletz featured on Making It in Manufacturing podcast

evaluating a CDMO proposal and RFP process

Mabion’s Article about RFP process named one of the Top 10 Industry Insights of 2025 by Outsourced Pharma

Declaration of the objectives and scope of the European Biotech Act

Declaration of the objectives and scope of the European Biotech Act